Expertise in
7
conditions

Olafur G. Jonsson

Reykjavik, IS 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
7
conditions
Reykjavik, IS 

Overview

Olafur Jonsson practices practicing medicine in Reykjavik, Iceland.

Jonsson is highly rated in 7 conditions, according to our data. Their clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Childhood Acute Myeloid Leukemia, and Leukocytosis.

They are actively involved in clinical research, co-authoring 83 peer reviewed articles and participating in 2 clinical trials.

Locations

Reykjavik, Iceland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Enrollment Status: Recruiting
Publish Date: August 12, 2026
Intervention Type: Drug
Study Drugs: Doxorubicin, Vincristine, Dexamethasone, Inotuzumab, Imatinib, 6-Tioguanine, Blinatumomab
Study Phase: Phase 3
Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)
Glucarpidase (CPG2) Effect on Severe Delayed Methotrexate-clearance in Children Treated With High-dose Methotrexate in Acute Lymphoblastic Leukemia (ALL)
Enrollment Status: Completed
Publish Date: September 28, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

83 Total Publications

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.
CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.
Journal: Trials
Published: February 13, 2026

Frequently Asked Questions about Olafur G. Jonsson

Is Olafur G. Jonsson a top-rated expert for Acute Lymphoblastic Leukemia (ALL)?

MediFind is an objective health platform that identifies experts based on real-world data. Olafur G. Jonsson is classified as an Distinguished expert for Acute Lymphoblastic Leukemia (ALL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olafur G. Jonsson participate in research or clinical trials?

Yes. Olafur G. Jonsson has published 83 articles and abstracts on conditions like Acute Lymphoblastic Leukemia (ALL). You can view a list of Olafur G. Jonsson's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Jonsson's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile